Declines and pronounced regional disparities in meperidine use in the United States
Authors:
Open Access
- 14 June 2021
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (4) , e00809
Abstract
There have been increasing concerns about adverse effects and drug interactions with meperidine. The goal of this study was to characterize meperidine use in the United States. Meperidine distribution data were obtained from the Drug Enforcement Administration's Automated of Reports and Consolidated Orders System. The Medicare Part D Prescriber Public Use File was utilized to capture overall trends in national prescriptions in this observational report. Nationally, meperidine distribution decreased by 94.6% from 2001 to 2019. In 2019, Arkansas, Alabama, Oklahoma, and Mississippi saw significantly greater distribution when compared with the US state average of 9.27 mg per 10 persons (SD = 6.82). Meperidine distribution showed an 18‐fold difference between the highest state (Arkansas = 36.8 mg) and lowest state (Minnesota = 2.1 mg). Five of the six states with the lowest distribution were in the Northeast. Meperidine distribution per state was correlated with the prevalence of adult obesity (r(48) = +0.48, p < .001). Family medicine and internal medicine physicians accounted for 28.9% and 20.5%, respectively, of meperidine total daily supply (TDS) in 2017. Interventional pain management (5.66) and pain management (3.48) physicians accounted for the longest TDS per provider. The use of meperidine declined over the last two decades. Meperidine varied by geographic region with south‐central states, and those with more obesity, showing greater distribution. Primary care doctors continue to account for the majority of meperidine daily supply. Increasing knowledge of meperidine's undesirable adverse effects like seizures and serious drug–drug interactions is likely responsible for these pronounced reductions.Keywords
All Related Versions
Funding Information
- Health Resources and Services Administration (D34HP31025)
- National Institute of Environmental Health Sciences (T32 ES007060‐31A1)
This publication has 25 references indexed in Scilit:
- Obesity as a risk factor for severe acute pancreatitis patientsWiener klinische Wochenschrift, 2014
- Factors Impacting Variability of the Urinary Normeperidine-to-Meperidine Metabolic Ratio in Patients with Chronic PainJournal of Analytical Toxicology, 2013
- The Epidemiology of Pancreatitis and Pancreatic CancerGastroenterology, 2013
- Serotonin syndrome.2013
- Meperidine-induced serotonin syndrome in a susceptible patientBritish Journal of Anaesthesia, 2009
- Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) miceInternational Journal of Neuropsychopharmacology, 2009
- An anthology from Naunyn-Schmiedeberg’s archives of pharmacologyNaunyn-Schmiedeberg's Archives of Pharmacology, 2007
- An analysis of the significant variation in psychostimulant use across the U.S.Pharmacoepidemiology and Drug Safety, 2005
- ‘Designer Drugs’Medical Toxicology, 1988
- Central nervous system excitatory effects of meperidine in cancer patientsAnnals of Neurology, 1983